Global Veterinary Vaccines Market Report and Forecast 2023-2031
Global Veterinary Vaccines Market Outlook
The global veterinary vaccines market value was USD 10.1 billion in 2022, driven by the rising prevalence of zoonotic diseases structure across the globe. The market size is anticipated to grow at a CAGR of 6.2% during the forecast period of 2023-2031 to achieve a value of USD 17.4 billion by 2031.
Veterinary Vaccines Introduction
Veterinary vaccines are essential for preventing and controlling infectious diseases in animals, ensuring animal health and welfare, and safeguarding public health. These vaccines play a crucial role in maintaining the health of livestock, poultry, and companion animals by stimulating their immune systems to produce a specific immune response against pathogens. Veterinary vaccines also help improve animal productivity and reduce the use of antibiotics, contributing to the fight against antimicrobial resistance.
The global veterinary vaccines market is experiencing significant growth due to factors such as the increasing demand for livestock products, the rising prevalence of zoonotic diseases, growing pet ownership, and the need for effective disease prevention in animals. Technological advancements in vaccine development, such as recombinant vaccines and DNA vaccines, are further driving the market. Additionally, government initiatives and investments in veterinary healthcare and research are contributing to the market's expansion.
Veterinary Vaccines Market Scenario
The global veterinary vaccines market is poised for significant growth as the demand for effective disease prevention in animals continues to rise. Factors such as the increasing demand for livestock products, the rising prevalence of zoonotic diseases, and technological advancements in vaccine development contribute to the market's expansion. The market is characterized by regional dynamics shaped by veterinary healthcare infrastructure, government support, and investment in research and development. However, challenges such as the high cost of vaccine development, limited access to vaccines in low- and middle-income countries, and the need for maintaining cold chain logistics may impact market growth.
North America: The largest market for veterinary vaccines, driven by factors such as advanced veterinary healthcare infrastructure, the presence of leading vaccine manufacturers, and a high focus on animal health and welfare.
Europe: The second-largest market, with increasing demand for veterinary vaccines due to a growing emphasis on food safety, animal welfare, and government support for research and development.
Asia-Pacific: Expected to witness the highest growth rate due to factors such as a rapidly growing livestock industry, increasing pet ownership, and growing investments in veterinary healthcare infrastructure and research.
Veterinary Vaccines Market Segmentations
Market Breakup by Type
- Live Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- DNA Vaccines
- Recombinant Vaccines
- Other Vaccines
- Porcine
- Poultry
- Livestock
- Bovine
- Small Ruminant
- Companion Animal
- Canine
- Feline
- Aquaculture
- Others
- Oral
- Parenteral
- Topical
- Veterinary Hospitals
- Veterinary Clinics
- Poultry Farms
- Animal Farms
- Others
- Online Stores
- Pharmacies and Drug Stores
- Others
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Trends in the Veterinary Vaccines Market
Some key trends of the market are as follows:
- Increasing demand for livestock products: The rising demand for livestock products, such as meat, milk, and eggs, is driving the need for effective vaccines to ensure the health and productivity of livestock animals.
- Growing prevalence of zoonotic diseases: The increasing occurrence of zoonotic diseases, which can be transmitted between animals and humans, is prompting the adoption of veterinary vaccines to protect public health.
- Technological advancements in vaccine development: The introduction of advanced vaccine technologies, such as recombinant and DNA vaccines, has improved the efficacy and safety of veterinary vaccines, leading to increased adoption.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the Veterinary Vaccines market are as follows:
- Bayer AG
- Sanofi
- Pfizer Inc.
- GSK plc.
- Merck & Co., Inc.
- Ceva
- Cargill, Incorporated
- Boehringer Ingelheim International GmbH.
- Takeda Pharmaceutical Company Limited
- Zoetis
- Dechra Pharmaceuticals PLC
- Hester Biosciences Limited.
- Elanco
- Phibro Animal Health Corporation
- Indovax
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Veterinary Vaccines Market Overview
- 3.1 Global Veterinary Vaccines Market Historical Value (2016-2022)
- 3.2 Global Veterinary Vaccines Market Forecast Value (2023-2031)
- 4 Global Veterinary Vaccines Market Landscape
- 4.1 Global Veterinary Vaccines Developers Landscape
- 4.1.0 Analysis by Year of Establishment
- 4.1.1 Analysis by Company Size
- 4.1.2 Analysis by Region
- 4.2 Global Veterinary Vaccines Product Landscape
- 4.2.0 Analysis by Type
- 4.2.1 Analysis by Animal Type
- 4.2.2 Analysis by End User
- 5 Global Veterinary Vaccines Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Veterinary Vaccines Market Segmentation
- 6.1 Global Veterinary Vaccines Market by Type
- 6.1.0 Market Overview
- 6.1.1 Live Attenuated Vaccines
- 6.1.2 Inactivated Vaccines
- 6.1.3 Toxoid Vaccines
- 6.1.4 DNA Vaccines
- 6.1.5 Recombinant Vaccines
- 6.1.6 Other Vaccines
- 6.2 Global Veterinary Vaccines Market by Animal Type
- 6.2.0 Market Overview
- 6.2.1 Porcine
- 6.2.2 Poultry
- 6.2.3 Livestock
- 6.2.3.1 Bovine
- 6.2.3.2 Small Ruminant
- 6.2.4 Companion Animal
- 6.2.4.1 Canine
- 6.2.4.2 Feline
- 6.2.5 Aquaculture
- 6.2.6 Others
- 6.3 Global Veterinary Vaccines Market by Route of Administration
- 6.3.0 Market Overview
- 6.3.1 Oral
- 6.3.2 Parenteral
- 6.3.3 Topical
- 6.4 Global Veterinary Vaccines Market by End User
- 6.4.0 Market Overview
- 6.4.1 Veterinary Hospitals
- 6.4.2 Veterinary Clinics
- 6.4.3 Poultry Farms
- 6.4.4 Animal Farms
- 6.4.5 Others
- 6.5 Global Veterinary Vaccines Market by Distribution Channel
- 6.5.0 Market Overview
- 6.5.1 Online Stores
- 6.5.2 Pharmacies and Drug Stores
- 6.5.3 Others
- 6.6 Global Veterinary Vaccines Market by Region
- 6.6.1 Market Overview
- 6.6.2 North America
- 6.6.3 Europe
- 6.6.4 Asia Pacific
- 6.6.5 Latin America
- 6.6.6 Middle East and Africa
- 7 North America Veterinary Vaccines Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Veterinary Vaccines Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Veterinary Vaccines Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Veterinary Vaccines Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Veterinary Vaccines Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
- 14.1 Analysis by Trial Registration Year
- 14.2 Analysis by Trial Status
- 14.3 Analysis by Trial Phase
- 14.4 Analysis by Therapeutic Area
- 14.5 Analysis by Geography
- 15 Funding Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.1.0 US FDA
- 17.1.1 EU EMA
- 17.1.2 INDIA CDSCO
- 17.1.3 JAPAN PMDA
- 17.1.4 Others
- 18 Supplier Landscape
- 18.1 Bayer AG
- 18.1.0 Financial Analysis
- 18.1.1 Product Portfolio
- 18.1.2 Demographic Reach and Achievements
- 18.1.3 Mergers and Acquisitions
- 18.1.4 Certifications
- 18.2 Sanofi
- 18.2.0 Financial Analysis
- 18.2.1 Product Portfolio
- 18.2.2 Demographic Reach and Achievements
- 18.2.3 Mergers and Acquisitions
- 18.2.4 Certifications
- 18.3 Pfizer Inc.
- 18.3.0 Financial Analysis
- 18.3.1 Product Portfolio
- 18.3.2 Demographic Reach and Achievements
- 18.3.3 Mergers and Acquisitions
- 18.3.4 Certifications
- 18.4 GSK plc.
- 18.4.0 Financial Analysis
- 18.4.1 Product Portfolio
- 18.4.2 Demographic Reach and Achievements
- 18.4.3 Mergers and Acquisitions
- 18.4.4 Certifications
- 18.5 Merck & Co., Inc.
- 18.5.0 Financial Analysis
- 18.5.1 Product Portfolio
- 18.5.2 Demographic Reach and Achievements
- 18.5.3 Mergers and Acquisitions
- 18.5.4 Certifications
- 18.6 Ceva
- 18.6.0 Financial Analysis
- 18.6.1 Product Portfolio
- 18.6.2 Demographic Reach and Achievements
- 18.6.3 Mergers and Acquisitions
- 18.6.4 Certifications
- 18.7 Cargill, Incorporated
- 18.7.0 Financial Analysis
- 18.7.1 Product Portfolio
- 18.7.2 Demographic Reach and Achievements
- 18.7.3 Mergers and Acquisitions
- 18.7.4 Certifications
- 18.8 Boehringer Ingelheim International GmbH.
- 18.8.0 Financial Analysis
- 18.8.1 Product Portfolio
- 18.8.2 Demographic Reach and Achievements
- 18.8.3 Mergers and Acquisitions
- 18.8.4 Certifications
- 18.9 Takeda Pharmaceutical Company Limited
- 18.9.0 Financial Analysis
- 18.9.1 Product Portfolio
- 18.9.2 Demographic Reach and Achievements
- 18.9.3 Mergers and Acquisitions
- 18.9.4 Certifications
- 18.10 Zoetis
- 18.10.0 Financial Analysis
- 18.10.1 Product Portfolio
- 18.10.2 Demographic Reach and Achievements
- 18.10.3 Mergers and Acquisitions
- 18.10.4 Certifications
- 18.11 Dechra Pharmaceuticals PLC
- 18.11.0 Financial Analysis
- 18.11.1 Product Portfolio
- 18.11.2 Demographic Reach and Achievements
- 18.11.3 Mergers and Acquisitions
- 18.11.4 Certifications
- 18.12 Hester Biosciences Limited.
- 18.12.0 Financial Analysis
- 18.12.1 Product Portfolio
- 18.12.2 Demographic Reach and Achievements
- 18.12.3 Mergers and Acquisitions
- 18.12.4 Certifications
- 18.13 Elanco
- 18.13.0 Financial Analysis
- 18.13.1 Product Portfolio
- 18.13.2 Demographic Reach and Achievements
- 18.13.3 Mergers and Acquisitions
- 18.13.4 Certifications
- 18.14 Phibro Animal Health Corporation
- 18.14.0 Financial Analysis
- 18.14.1 Product Portfolio
- 18.14.2 Demographic Reach and Achievements
- 18.14.3 Mergers and Acquisitions
- 18.14.4 Certifications
- 18.15 Indovax
- 18.15.0 Financial Analysis
- 18.15.1 Product Portfolio
- 18.15.2 Demographic Reach and Achievements
- 18.15.3 Mergers and Acquisitions
- 18.15.4 Certifications
- 19 Global Veterinary Vaccines Market - Distribution Model (Additional Insight)
- 19.1 Overview
- 19.2 Potential Distributors
- 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 21 Company Competitiveness Analysis (Additional Insight)
- 21.1 Very Small Companies
- 21.2 Small Companies
- 21.3 Mid-Sized Companies
- 21.4 Large Companies
- 21.5 Very Large Companies
- 22 Payment Methods (Additional Insight)
- 22.1 Government Funded
- 22.2 Private Insurance
- 22.3 Out-of-Pocket
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook